Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v12-FR
Language French French
Date Updated 2023-01-23 2023-01-10
Drug Identification Number 02502399 02502399
Brand name HULIO HULIO
Common or Proper name ADALIMUMAB ADALIMUMAB
Company Name BIOSIMILAR COLLABORATIONS IRELAND LIMITED BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Ingredients ADALIMUMAB ADALIMUMAB
Strength(s) 40MG 40MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 x 0.8mL sterile solution (50mg/mL) subcutaneous injection (pre-filled syringe) 2 x 0.8mL sterile solution (50mg/mL) subcutaneous injection (pre-filled syringe)
ATC code L04AB L04AB
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-11-11 2022-11-11
Estimated end date 2023-01-18 2023-01-17
Actual end date 2023-01-19
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments